Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on June 30, 2026 by admin
<![CDATA[Explore 2024’s xanomeline–trospium: M1/M4 muscarinic therapy for schizophrenia, easing EPS and metabolic risks while raising GI concerns.]]>
CategoriesUncategorized TagsMedication, News Approved, Schizophrenia spectrum

Post navigation

Previous PostPrevious Midlands trust launches digital medicines management system
Next PostNext First Huntington’s Disease Patient Dosed with Neural Stem Cell Therapy
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.